BR122023024697A2 - Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana - Google Patents

Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana Download PDF

Info

Publication number
BR122023024697A2
BR122023024697A2 BR122023024697-7A BR122023024697A BR122023024697A2 BR 122023024697 A2 BR122023024697 A2 BR 122023024697A2 BR 122023024697 A BR122023024697 A BR 122023024697A BR 122023024697 A2 BR122023024697 A2 BR 122023024697A2
Authority
BR
Brazil
Prior art keywords
bacterial strain
negative bacterial
proteins
recombinant gram
protein
Prior art date
Application number
BR122023024697-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Simon Ittig
Marlise Amstutz
Christoph Kasper
Guy R. Cornelis
Original Assignee
Universität Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Basel filed Critical Universität Basel
Publication of BR122023024697A2 publication Critical patent/BR122023024697A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR122023024697-7A 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana BR122023024697A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15195490 2015-11-19
EP15195490.6 2015-11-19
PCT/EP2016/078084 WO2017085233A1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors
BR112018009753-5A BR112018009753B1 (pt) 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana

Publications (1)

Publication Number Publication Date
BR122023024697A2 true BR122023024697A2 (pt) 2023-12-26

Family

ID=54697464

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018009753-5A BR112018009753B1 (pt) 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana
BR122023024697-7A BR122023024697A2 (pt) 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112018009753-5A BR112018009753B1 (pt) 2015-11-19 2016-11-17 Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana

Country Status (24)

Country Link
US (1) US11166987B2 (enExample)
EP (2) EP3903813A1 (enExample)
JP (1) JP7060503B2 (enExample)
KR (1) KR102736981B1 (enExample)
CN (1) CN108472348B (enExample)
AU (1) AU2016358257B2 (enExample)
BR (2) BR112018009753B1 (enExample)
CA (1) CA3003563A1 (enExample)
CY (1) CY1124564T1 (enExample)
DK (1) DK3377094T3 (enExample)
EA (1) EA201890868A1 (enExample)
ES (1) ES2880431T3 (enExample)
HR (1) HRP20211191T1 (enExample)
HU (1) HUE055132T2 (enExample)
IL (1) IL259052B2 (enExample)
LT (1) LT3377094T (enExample)
PL (1) PL3377094T3 (enExample)
PT (1) PT3377094T (enExample)
RS (1) RS62152B1 (enExample)
SG (1) SG11201803643TA (enExample)
SI (1) SI3377094T1 (enExample)
SM (1) SMT202100423T1 (enExample)
WO (1) WO2017085233A1 (enExample)
ZA (1) ZA201803902B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046025T2 (hu) 2014-05-21 2020-01-28 Univ Basel Baktérium-alapú fehérjeszállítás
PT3377634T (pt) 2015-11-19 2020-11-16 Univ Basel Distribuição de proteínas baseada em bactérias
SMT202100537T1 (it) 2016-12-20 2021-11-12 Univ Basel Veicolazione di proteine basata su batteri con virulenza attenuata
KR102110993B1 (ko) * 2018-12-20 2020-05-14 한국생명공학연구원 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물
EP4237429A1 (en) * 2020-10-27 2023-09-06 T3 Pharmaceuticals AG Bacteria based protein delivery
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用
CN116064877B (zh) * 2023-02-09 2024-09-20 宁夏大学 利用lamp技术快速检测阴沟肠杆菌的试剂盒及方法
CN116855496B (zh) * 2023-07-05 2024-08-16 郑州大学 含有干扰序列siRNA-HIF-1α的表达质粒在制备抗肝细胞癌药物中的应用
WO2025037284A2 (en) * 2023-08-17 2025-02-20 Baccine Ltd. Genetically modified bacteria for multi-modal secretion of a neoantigen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
AU5209399A (en) 1998-07-10 2000-02-01 Cornell Research Foundation Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
AU2001294834A1 (en) 2000-09-26 2002-04-08 Beth Israel Deaconess Medical Center Recombinant bcg vaccines for the prevention and treatment of cancer
AU2002312778A1 (en) 2001-03-26 2002-10-08 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
AU2003282337B2 (en) * 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
EP1943344A2 (en) 2005-10-04 2008-07-16 The Ludwig Institute for Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2009115531A2 (en) 2008-03-17 2009-09-24 Universitätsklinikum Münster Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
WO2012167368A1 (en) * 2011-06-08 2012-12-13 Chelation Partners Incorporated Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
US9127284B2 (en) * 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
HUE046025T2 (hu) 2014-05-21 2020-01-28 Univ Basel Baktérium-alapú fehérjeszállítás
PT3377634T (pt) 2015-11-19 2020-11-16 Univ Basel Distribuição de proteínas baseada em bactérias
SMT202100537T1 (it) 2016-12-20 2021-11-12 Univ Basel Veicolazione di proteine basata su batteri con virulenza attenuata

Also Published As

Publication number Publication date
SMT202100423T1 (it) 2021-09-14
EP3903813A1 (en) 2021-11-03
EP3377094B1 (en) 2021-04-28
PL3377094T3 (pl) 2021-12-13
WO2017085233A1 (en) 2017-05-26
SG11201803643TA (en) 2018-06-28
US20190015497A1 (en) 2019-01-17
AU2016358257A1 (en) 2018-05-10
KR20180081583A (ko) 2018-07-16
RS62152B1 (sr) 2021-08-31
DK3377094T3 (da) 2021-08-02
EP3377094A1 (en) 2018-09-26
ZA201803902B (en) 2019-03-27
JP2019500026A (ja) 2019-01-10
HUE055132T2 (hu) 2021-11-29
US11166987B2 (en) 2021-11-09
AU2016358257B2 (en) 2023-08-17
PT3377094T (pt) 2021-07-08
JP7060503B2 (ja) 2022-04-26
CN108472348A (zh) 2018-08-31
CN108472348B (zh) 2022-12-27
BR112018009753A2 (pt) 2018-11-13
IL259052B1 (en) 2023-11-01
KR102736981B1 (ko) 2024-12-02
IL259052B2 (en) 2024-03-01
LT3377094T (lt) 2021-08-10
HRP20211191T1 (hr) 2021-10-29
CA3003563A1 (en) 2017-05-26
ES2880431T3 (es) 2021-11-24
BR112018009753B1 (pt) 2024-02-20
IL259052A (en) 2018-07-31
HK1256137A1 (en) 2019-09-13
SI3377094T1 (sl) 2021-09-30
EA201890868A1 (ru) 2018-12-28
CY1124564T1 (el) 2022-07-22
BR112018009753A8 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
ES2880431T3 (es) Bacterias de virulencia atenuada para el tratamiento de tumores sólidos malignos
US11702663B2 (en) Bacteria-based protein delivery
ES2754508T3 (es) Transporte de proteínas basado en bacterias
EA040558B1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
HK1256137B (en) Virulence attenuated bacteria for treatment of malignant solid tumors
CA3005380C (en) Bacteria-based protein delivery
BR112018009782B1 (pt) Cepas bacterianas recombinantes gram-negativas transformadas com um vetor e vetores
HK1256138B (en) Bacteria-based protein delivery
BR122024010821A2 (pt) Cepa bacteriana gram-negativa recombinante de virulência atenuada e seu uso

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]